10-Q: ENDRA Life Sciences Reports Q1 2025 Results: Focus Shifts to Commercialization Amidst Financial Challenges

ENDRA Life Sciences reports a reduced net loss for Q1 2025 compared to Q1 2024, as the company focuses on commercializing its TAEUS technology while addressing ongoing financial challenges.

Summary

• ENDRA Life Sciences Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is developing its Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, with an initial focus on measuring liver fat.
• ENDRA aims to become a biomarker solution provider for metabolic diseases and GLP-1 drug management.
• The company is targeting pharmaceutical companies, clinical research organizations, high-end primary care networks, bariatric clinics, and primary care physicians.
• For the three months ended March 31, 2025, ENDRA reported a net loss of $1,036,330, compared to a net loss of $2,775,700 for the same period in 2024.
• Research and development expenses decreased to $528,685 from $1,041,526 year-over-year.
• Sales and marketing expenses also decreased to $68,991 from $238,660 year-over-year.
• General and administrative expenses decreased to $871,606 from $1,500,355 year-over-year.
• As of March 31, 2025, ENDRA had cash of $2,064,874 and an accumulated deficit of $104,474,429.
• The company is actively seeking additional financing to fund its operations and commercialization efforts.
• ENDRA issued 25,305 shares of common stock under the February 2024 ATM Agreement, generating net proceeds of $145,803.
• Subsequent to the quarter, ENDRA issued 176,157 shares of common stock for gross proceeds of $834,353 under the ATM agreement.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is reducing losses and focusing on commercialization, it faces significant financial challenges and needs to raise additional capital. The material weakness in internal controls is also a concern.

Positives

• The net loss decreased significantly from Q1 2024 to Q1 2025, indicating improved cost management.
• Research and development, sales and marketing, and general and administrative expenses all decreased, reflecting a focus on efficiency.
• The company is actively pursuing commercialization of its TAEUS technology, which could lead to future revenue generation.
• ENDRA is targeting specific markets with its TAEUS platform, including pharmaceutical companies and primary care networks.
• The company is leveraging artificial intelligence and machine learning to improve the accuracy of its TAEUS technology.
• ENDRA is implementing a subscription-based business model to generate recurring revenue.
• Subsequent to the quarter, ENDRA issued 176,157 shares of common stock for gross proceeds of $834,353 under the ATM agreement.

Negatives

• ENDRA has a significant accumulated deficit of $104,474,429 as of March 31, 2025.
• The company has not generated any revenue from its TAEUS technology as of March 31, 2025.
• ENDRA's cash balance of $2,064,874 as of March 31, 2025, is relatively low, raising concerns about its ability to fund operations.
• The company needs to raise additional capital to continue its operations and commercialization efforts.
• ENDRA's disclosure controls and procedures were deemed not effective due to insufficient personnel resources within the accounting function.
• The company is experiencing financial and operating challenges, which could force it to delay or reduce its product development programs and commercialization efforts.

Risks

• ENDRA's limited commercial experience and history of losses pose a significant risk.
• The company's ability to obtain adequate financing to fund its business operations is uncertain.
• Market acceptance of ENDRA's TAEUS technology is not guaranteed.
• Results of human studies may be negative or inconclusive.
• The company relies on collaborations and strategic alliances, which may not be successful.
• Changes in the healthcare industry or third-party reimbursement practices could negatively impact ENDRA.
• Delays in regulatory requirements and approvals could hinder the company's progress.
• ENDRA's ability to regain compliance with the listing standards of the Nasdaq Capital Market is uncertain.
• The company identified a material weakness in its internal control over financial reporting.

Future Outlook

ENDRA expects to continue incurring significant expenses as it advances its TAEUS technology and pursues FDA approval. The company will need to raise additional capital to fund its operations and commercialization plans. ENDRA is considering potential financing options, such as sales of its common stock through its at-the-market sales program.

Management Comments

• Management plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing.
• Management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

Industry Context

ENDRA is positioning its TAEUS technology as a solution for the growing market of metabolic diseases and GLP-1 drug management. The company is targeting pharmaceutical companies and clinical research organizations involved in developing new GLP-1 therapeutics. ENDRA is also focusing on primary care networks and bariatric clinics for the management of obesity and liver disease.

Comparison to Industry Standards

• It's difficult to directly compare ENDRA's results to industry standards due to its unique technology and stage of development.
• However, similar early-stage medical device companies often face challenges in generating revenue and require significant investment in research and development.
• Companies like Butterfly Network (portable ultrasound) and Intersect ENT (ENT medical devices) have faced similar challenges in achieving profitability.
• ENDRA's success will depend on its ability to secure regulatory approvals, demonstrate clinical efficacy, and establish a strong commercial presence.
• The company's focus on the metabolic disease market aligns with growing trends in healthcare, but competition from established players remains a risk.

Management Changes

Legal Proceedings

• As of March 31, 2025, there were no legal matters that management believes would have a material effect on the Company's financial position or results of operations.

Related Party Transactions

• In the first quarter of 2025, Impact Solutions and IS Bookkeeping & Payroll provided services to the Company totaling $35,926 and $13,260, respectively.
• The Company's Chief Financial Officer works in a part-time capacity for the Company through Impact Solutions.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential delays or reductions in product development programs and commercialization efforts.
• Customers may experience delays in the availability of ENDRA's TAEUS technology.
• Suppliers and creditors face the risk of non-payment if the company's financial condition deteriorates.

Next Steps

• ENDRA plans to continue developing its TAEUS technology and pursue FDA approval.
• The company will focus on commercializing its TAEUS technology and establishing key biomarkers for metabolic diseases management.
• ENDRA will seek to raise additional capital to fund its operations and commercialization plans.
• The company intends to implement measures to remediate the material weakness in its internal control over financial reporting.

Key Dates

Keywords

TAEUS, ENDRA, Life Sciences, Q1 2025, Financial Results, Liver Fat, Metabolic Diseases, GLP-1, Commercialization, ATM Agreement, Thermo-Acoustic Enhanced Ultrasound